Xencor Revises Revenue Forecast Amid Royalty Dispute with Alexion Over Ultomiris

Key Facts

1Alexion Pharmaceuticals informed Xencor that it believes it does not owe any additional royalties for sales of Ultomiris in the United States.

2Xencor announced a change to its royalty revenue forecast as a result of this dispute.

3Xencor is a clinical-stage company that relies on such revenues to fund drug development.

Xencor, Inc. has announced a significant dispute with Alexion Pharmaceuticals regarding royalty payments for the drug Ultomiris in the United States. Alexion informed the company that it believes no further royalties are owed for US sales under their existing licensing agreement. Consequently, Xencor has been forced to downwardly revise its royalty revenue projections, impacting its overall financial outlook. As a clinical-stage biotech firm, Xencor relies heavily on these recurring revenues to fund its various drug development programs. The loss of expected cash flow poses a strategic challenge for the company's research and development pipeline and operational runway. Market analysts are closely watching how this disagreement will affect Xencor’s long-term capital position and its ability to sustain future clinical trials.